GlobeNewswire Inc.··NaGyre Therapeutics Posts 10% Revenue Growth but Guides Lower Amid Strategic Pivot
Gyre Therapeutics posts 10% FY2025 revenue growth to $116.6M, guides 2026 lower due to regulatory prioritization and Cullgen acquisition for TPD expansion.
GYRErevenue guidanceclinical trial